[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352064-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352064-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","nanotechnology-in-prostate-cancer-psma-targeted-nanoplatforms-tme-responsive-therapy-immunomodulation-and-clinical-translation-challenges","Nanotechnology in Prostate Cancer - PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges","","Nanotechnology demonstrates substantial potential for diagnosing and treating prostate cancer through PSMA-targeted platforms and tumor microenvironment (TME)-responsive systems. Molecular imaging probes improve sensitivity and specificity, while nanostructured liquid biopsy platforms capture circulating tumor cells, exosomes, and circulating tumor DNA for non-invasive monitoring. Therapeutic nanocarriers enhance delivery of chemotherapeutics, gene-editing tools, and immunomodulators using pH, enzyme, and redox triggered release. Strategies address castration-resistant drug resistance via protein degradation, ferroptosis, and chemoimmunotherapy, though translational barriers remain.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nanotechnology-in-prostate-cancer-psma-targeted-nanoplatforms-tme-responsive-therapy-immunomodulation-and-clinical-translation-challenges/352064/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nanotechnology-in-prostate-cancer-psma-targeted-nanoplatforms-tme-responsive-therapy-immunomodulation-and-clinical-translation-challenges/352064.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do PSMA-targeted nanoparticle platforms support diagnosis of prostate cancer?","Question",{"text":63,"@type":64},"PSMA-targeted molecular imaging probes enhance detection sensitivity and specificity. Examples include superparamagnetic iron oxide for magnetic resonance imaging and near-infrared fluorescent nanomicelles.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do TME-responsive systems play in prostate cancer therapy using nanotechnology?",{"text":68,"@type":64},"TME-responsive mechanisms such as pH, enzyme, and redox enable spatiotemporal control of drug release. This improves delivery effectiveness for chemotherapeutics, gene-editing tools, and immunomodulators.",{"name":70,"@type":61,"acceptedAnswer":71},"What major barriers limit clinical translation of nanomedicines for prostate cancer?",{"text":72,"@type":64},"Key challenges include heterogeneous PSMA expression (with many PSMA-negative cases), suboptimal enhanced permeability and retention in humans, long-term safety concerns, manufacturing hurdles, and regulatory gaps.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352064,1790663003,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nNanotechnology in Prostate Cancer:  \nPSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges  \nWenjian Li   \nDepartment of Urology, The Affiliated Changzhou Hospital of Xuzhou Medical University, Changzhou Third People’s Hospital, Changzhou, Jiangsu, People’s Republic of China  \nCorrespondence: Wenjian Li, Department of Urology, The Affiliated Changzhou Hospital of Xuzhou Medical University, Changzhou Third People’s Hospital, Changzhou, Jiangsu, People’s Republic of China, Tel +86-0519-82009022, Email [bolite@163.com](bolite@163.com)  \n\n| Abstract: The field of nanotechnology has demonstrated considerable potential in the diagnosis and treatment of prostate cancer, particularly through the use of prostate-specific membrane antigen (PSMA)-targeted platforms and tumor microenvironment (TME) -responsive systems. In the context of diagnosis, nanoparticle-based molecular imaging probes have been shown to enhance detection sensitivity and specificity. These probes include superparamagnetic iron oxide, which is utilized in magnetic resonance imaging, and near-infrared fluorescent nanomicelles. Additionally, nanostructured liquid biopsy systems have demonstrated the capability to capture circulating tumor cells, exosomes, and circulating tumor DNA with high sensitivity, facilitating non-invasive genotyping and treatment monitoring. In the field of therapeutics, PSMA-targeted liposomes, polymeric nanoparticles, and inorganic nanocarriers have demonstrated efficacy in enhancing the delivery of chemotherapeutics, gene-editing tools (eg, CRISPR/Cas9, siRNA), and immunomodulators. These delivery mechanisms are equipped with TME-responsive release mechanisms (eg, pH, enzyme, redox) that enable thespatiotemporal control of drug release. Nanotechnology offers multi-level strategies to overcome multidrug resistance in castrationresistant prostate cancer, including PROTAC-mediated protein degradation, ferroptosis induction, and synergistic chemoimmunotherapy. Multifunctional theranostic nanoplatforms integrating imaging and therapy enable real-time efficacy assessment and personalized treatment adaptation. Emerging green synthesis approaches that utilize agricultural byproducts and bio-inspired platforms (eg, cell membrane-coated nanoparticles) present sustainable and biocompatible alternatives. Concurrently, artificial intelligence (AI) holds the potential to expedite the design of nanocarriers. Despite the advancement of several nanomedicines to clinical trials, significant translational barriers persist. These include heterogeneous PSMA expression (15–37% of castration-resistant prostate cancer cases are PSMA-negative), suboptimal enhanced permeability and retention effect in humans, long-term safety concerns, manufacturing hurdles, and regulatory gaps. This narrative review methodically examines the applications of nanotechnology in prostate cancer. It critically analyzes the clinical translation challenges encountered during clinical trials and discusses future directions, including smart responsive systems, multimodal immunotherapy, and AI-assisted nanomedicine design.\u003Cbr>Keywords: nanotechnology, prostate cancer, targeted delivery, integrated diagnosis and treatment, clinical translation |\n| --- |\n| Introduction\u003Cbr>Prostate cancer is among the most prevalent malignancies affecting the male urinary system.1,2 On a global scale, this type of cancer ranks second in incidence and fifth in mortality among male cancers.3 According to GLOBOCAN 2022 data, approximately 1.47 million new cases of prostate cancer were diagnosed worldwide in 2022, resulting in approximately 390,000 deaths.3 The risk of developing prostate cancer increases significantly with age. The high detection rate of prostate cancer can be attributed to two major factors: population aging and the widespread adoption of prostate-specific antigen (PSA)","cbCaieto8KBqYGE8","https://ap.wps.com/l/cbCaieto8KBqYGE8","pdf",4099527,31,"English","# Abstract\n# Introduction\n## Prostate cancer burden and screening limitations\n# Nanotechnology in diagnosis and molecular imaging\n## PSMA-targeted imaging probes\n## Liquid biopsy-based detection\n# Nanotechnology in therapeutics\n## PSMA-targeted nanocarriers and drug/gene delivery\n## TME-responsive release mechanisms\n# Overcoming resistance and theranostic platforms\n## Multifunctional imaging-therapy integration\n## Strategies against multidrug resistance\n# Emerging approaches and future directions\n## Green synthesis and bio-inspired platforms\n## AI-assisted nanocarrier design\n# Clinical translation challenges\n## PSMA heterogeneity, safety, manufacturing, and regulation","[{\"question\":\"How do PSMA-targeted nanoparticle platforms support diagnosis of prostate cancer?\",\"answer\":\"PSMA-targeted molecular imaging probes enhance detection sensitivity and specificity. Examples include superparamagnetic iron oxide for magnetic resonance imaging and near-infrared fluorescent nanomicelles.\"},{\"question\":\"What role do TME-responsive systems play in prostate cancer therapy using nanotechnology?\",\"answer\":\"TME-responsive mechanisms such as pH, enzyme, and redox enable spatiotemporal control of drug release. This improves delivery effectiveness for chemotherapeutics, gene-editing tools, and immunomodulators.\"},{\"question\":\"What major barriers limit clinical translation of nanomedicines for prostate cancer?\",\"answer\":\"Key challenges include heterogeneous PSMA expression (with many PSMA-negative cases), suboptimal enhanced permeability and retention in humans, long-term safety concerns, manufacturing hurdles, and regulatory gaps.\"}]","Nanotechnology in Prostate Cancer - PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges | PDF",1790097519,78,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa497e4f22a2776885b03b42b8c17804.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/135c08be10e6aa52b604969e02ad9638.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83c945fcfce26a74ab987eaef14a8558.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e170d9721300ab8fdcfd4b81238669b.webp",980,1268]